Berge will serve in this role through the end of 2026, marking another milestone in her successful career in healthcare.
Leanne Berge, chief executive officer of Community Health Plan of Washington (CHPW), has recently been elected as chair of Association for Community Affiliated Plans’ (ACAP) board of directors.
Berge will serve in this role through the end of 2026, marking another milestone in her successful career in healthcare.
Berge
ACAP represents 84 health plans across the nation, collectively providing health coverage to over 30 million individuals. The organization’s mission focuses on strengthening the nation’s safety net and advocating for folks relying on Medicaid, Medicare and Marketplace plans.
ACAP CEO Margaret A. Murray, who is also a member of Managed Healthcare Executive’s Editorial Advisory Board, expressed confidence in Berge’s ability to lead the association.
“Leanne is a proven leader with a career in health care spanning four decades,” said Murray. “I am confident that her vision and guidance will ensure that the Association continues its longstanding commitment to strengthening our nation’s safety net.”
Berge brings much experience in the industry to her role at ACAP.
At CHPW, she has worked to reduce health inequalities and make care more accessible by addressing issues including language barriers, access to care and geographic challenges.
Under her leadership, CHPW has focused on whole-person health by integrating physical and mental health services while addressing critical factors such as housing and maternal health.
CHPW’s commitment to equity is clear through their Advancing Equity Fund, which recently donated $250,000 to 25 local groups supporting immigrant, refugee, LGBTQ+ and BIPOC communities. Since 2020, CHPW has donated over $1.2 million to 81 organizations statewide.
Reflecting on her new role, Berge said she was honored for the opportunity.
“I’m honored for the opportunity to serve ACAP’s membership, particularly at a time where the Medicaid program may be at an inflection point,” Berge said. “As chair, I look forward to working alongside my fellow Safety Net Health Plan leaders as we continue our advocacy on behalf of the 30 million enrollees who rely on us for comprehensive health care. Safety Net Health Plans are mission-focused and put people first—that will continue to be our driving force as we head into 2025 and beyond.”
Berge will serve alongside several prominent board members, including Eric Hunter, CEO of CareOregon, who is also a member of Managed Healthcare Executive’s Editorial Advisory Board.
Her new role as Chair of ACAP’s Board of Directors places her in a position to expand CHPW’s mission on a national scale, ensuring that underserved populations continue to receive the care they need.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More